We rely on your voice to advocate for our policy priorities. Join us to show our strength as a community that cares about endocrinology. Throughout the year, you will have the opportunity to participate in campaigns that support endocrinology research, care, professionals, and patients. Contact us to get more involved: [email protected].
On August 16, President Biden signed the Inflation Reduction Act into law. The law caps insulin’s out-of-pocket costs at $35 a month for people with Medicare, which will make insulin more affordable for the millions of people enrolled in the program. However, the Inflation Reduction Act did not include a similar provision for people under 65 and insulin remains unaffordable for the millions of people with private insurance. The Endocrine Society is urging Congress to pass legislation before the end of the year that would cap insulin at $35/month for people with private insurance. It’s imperative that you – the constituent – remind your Senators that addressing insulin affordability is a top priority.
On January 1, 2023 Medicare is scheduled to cut payments for certain health care providers by over 8%. These cuts would significantly affect endocrinologists and the important work you do to care for older Americans living with diabetes, obesity, thyroid disease, and other endocrine disorders.
The Endocrine Society is urging Congress to avert these cuts. It is critical that all members of Congress hear from YOU, their constituents, about the need to address these cuts before the end of the year.
Congress was not able to complete appropriations for FY 2023 by September 30, and instead passed a short-term continuing resolution (CR) through December 16. While a CR averts a government shutdown, it continues to fund the NIH at FY 2022 levels and does not account for increases in biomedical research inflation. We are urging Congress to pass a final appropriations bill as soon as possible that includes at least $50 billion for the base budget for the National Institutes of Health (NIH).
The Endocrine Society is urging Congress to help researchers recover from the COVID-19 pandemic, restart their labs, and continue making progress on important research progress that was interrupted by the pandemic. The most promising vehicle for providing research relief through additional funds is the Research Investment to Spark the Economy (RISE) Act, which was introduced last year and has bipartisan support. The RISE Act would authorize approximately $25 billion in additional funds for research recovery, including nearly $10 billion for the NIH. While the bill has significant bipartisan support – they need more cosponsors to ensure that the Act makes it across the finish line!
Take action in our campaign and tell your Representative support the RISE Act so that our research community can recover from pandemic-related closures and other disruptions. Advocacy matters and if the research community is vocal about their needs, we can ensure that increased federal funds for research are consistent and sustainable.
Our advocacy calendar provides a global overview of upcoming legislative and regulatory deadlines and events.
Read our newsletters covering the latest science-based information on endocrine-disrupting chemicals (EDCs) for policymakers in the European Union.